JPS6050789B2 - Novel compound having bronchial secretagogue activity, mucus fluidizing activity and cough suppressant activity, process for producing the same, and pharmaceutical composition containing the same - Google Patents
Novel compound having bronchial secretagogue activity, mucus fluidizing activity and cough suppressant activity, process for producing the same, and pharmaceutical composition containing the sameInfo
- Publication number
- JPS6050789B2 JPS6050789B2 JP58142379A JP14237983A JPS6050789B2 JP S6050789 B2 JPS6050789 B2 JP S6050789B2 JP 58142379 A JP58142379 A JP 58142379A JP 14237983 A JP14237983 A JP 14237983A JP S6050789 B2 JPS6050789 B2 JP S6050789B2
- Authority
- JP
- Japan
- Prior art keywords
- activity
- same
- pharmaceutical composition
- thiazolidine
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
【発明の詳細な説明】
本発明は吸収、生物有用性及び組成レベルに関する有用
な薬動力学的特性のみならず、顕著な気管支分泌促進活
性、気管気管支粘液の流動化活性及び咳止め活性を有す
る新規な化合物に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention has significant bronchial secretagogue activity, tracheobronchial mucus fluidizing activity and cough suppressant activity, as well as useful pharmacodynamic properties with respect to absorption, bioavailability and compositional levels. Concerning new compounds.
ｊ 本発明による化合物は、次の一般式（Ｉ）で表わさ
れるグアヤコールＮ−アセチルー４−チアゾリジンーカ
ルボキシレートである。本発明のもう一つの目的は、こ
の化合物（１）の製法を提供することである。j The compound according to the present invention is guaiacol N-acetyl-4-thiazolidine-carboxylate represented by the following general formula (I). Another object of the present invention is to provide a method for producing this compound (1).
最後に、本発明の別の目的は、グアヤコールＮ−アセチ
ルー４−チアゾリジンーカルボキシレートにより形成さ
れるか、又はそれを活性成分として含有する気管支分泌
促進活性、粘液溶解活性及び咳止め活性を有する製薬組
成物を提供することである。Finally, another object of the invention is to provide pharmaceutical preparations with bronchial secretagogue, mucolytic and cough suppressant activity formed by or containing guaiacol N-acetyl-4-thiazolidine-carboxylate as an active ingredient. An object of the present invention is to provide a composition.
本発明によれば、化合物（１）（以下、単にＳＡ７３４
と略記する）は、４−チアゾリジンンーカルボン酸を出
発物資とし、それを塩基の存在下にアセチルクロライド
と反応させてアセチル化し、次いで得られたＮ−アセチ
ルー４−チアゾリジンーカルボン酸を無水の中性溶媒中
でグアヤコール（２−メトキシーフェノール）によりエ
ステル化することにより、製造される。According to the present invention, compound (1) (hereinafter simply SA734
(abbreviated as ) uses 4-thiazolidine-carboxylic acid as a starting material, reacts it with acetyl chloride in the presence of a base to acetylate it, and then converts the obtained N-acetyl-4-thiazolidine-carboxylic acid into anhydrous solution. It is produced by esterification with guaiacol (2-methoxyphenol) in a neutral solvent.
このようにして得られた化合物（１）は、カルボキシメ
チルスティン、α−メルカプトプロピオニルグリシン、
グアヤコール及びコデインのような既に治療に用いられ
ている他の薬剤に比べて、毒性がなく、気管支分泌促進
活性、咳止め活性及び粘液流動化活性で優れているとい
うことがわかつた。Compound (1) thus obtained contains carboxymethylstein, α-mercaptopropionylglycine,
It was found to be non-toxic and superior in bronchial secretagogue, cough suppressant and mucus fluidizing activities compared to other drugs already used in therapy such as guaiacol and codeine.
更に化合物ＳＡ７３４は、経口投与後によく吸収され、
チアゾリジンーカルボン酸を等モル量投与した場合と比
べて、原形質及び肺のレベルの面で明らかに一層高つか
つ長時間の間、チアゾリジンーカルボン酸を生成する。Furthermore, compound SA734 is well absorbed after oral administration;
Compared to equimolar doses of thiazolidine-carboxylic acid, the production of thiazolidine-carboxylic acid is clearly higher and for a longer time at plasma and lung levels.
ｃこのことからみて、ＳＡ７３
４は、吸収器に対して高い生物利用性と顕著な屈動性を
有するということがわかる。次の実施例は、本発明を説
明するものであるが、如何なる場合においても本発明を
限定するも４のではない。c Considering this, SA73
4 is found to have high bioavailability and significant flexibility for absorbers. The following examples illustrate the invention but do not limit it in any way.
実施例
Ａｌｌｙ（イ）．１１モル）の重炭酸カリウム及び８．
５ｍｔ（０．１０モル）のアセチルクロライド／２０ｍ
１のアセトンを攪拌しながら約１紛間で滴下することに
より、１３．３ｆ（０．１モル）の４−チアゾリジンー
カルボン酸／１００ｍＬのアセトンに加え、室温で丘時
間攪拌したのち、混合物を口過し、一 得られた沈澱物
をアセトンで完全に洗浄する。Example Ally (a). 11 mol) of potassium bicarbonate and 8.
5mt (0.10mol) acetyl chloride/20m
13.3 f (0.1 mol) of 4-thiazolidine-carboxylic acid/100 mL of acetone by dropping approximately 1 part of acetone with stirring, and after stirring at room temperature for an hour, the mixture was mixed. Pass through the mouth and thoroughly wash the resulting precipitate with acetone.
次に有機層を減圧で濃縮し、１２．７ｆの組生成物を
得たのち、これをアセトン／ジエチルエーテ混合液で再
結晶し、６ｙのＮ−アセチルー４一チアゾリジンーカル
ボン酸（Ｍ．Ｐ＝１３６−１３８０℃）を得る。Ｂ６．
５ｙのカルボニルージイミダゾールを５．５ｙ（４）．
０３１４モル）のＮ−アセチルー４−チアゾリジンーカ
ルボン酸に加え、炭酸ガスの発生が終つた時に、５ｙの
グアヤコール／１０ｍ１のテート５ ラヒドロフラン及
び０．１ｙのＭｅＯＮａを加える。Next, the organic layer was concentrated under reduced pressure to obtain a compound of 12.7f, which was recrystallized from an acetone/diethyl ether mixture to obtain 6y N-acetyl-4-thiazolidine-carboxylic acid (M.P = 136-1380°C). B6.
5y carbonyl diimidazole to 5.5y(4).
0.314 mol) of N-acetyl-4-thiazolidine-carboxylic acid, and when the evolution of carbon dioxide gas has ceased, 5y of guaiacol/10ml of tate5-lahydrofuran and 0.1y of MeONa are added.
温度を３紛間５０゜Ｃまで上昇させ、次いで混合物を
室温てｌ満間放置する。最後に、溶媒を減圧で蒸発させ
、残留物を水で洗浄したのち、ジエチルエーテルで抽出
する。ノ 有機層を無水Ｎａ２ｓＯ４の上で乾燥させ
たのち、口過し、溶媒を減圧で蒸発させて、８ｙの粗生
成物を得る。The temperature is raised to 50° C. and the mixture is then left at room temperature for 1 hour. Finally, the solvent is evaporated under reduced pressure and the residue is washed with water and then extracted with diethyl ether. After drying the organic layer over anhydrous Na2sO4, it is filtered and the solvent is evaporated under reduced pressure to obtain the crude product 8y.
ＳｌＯ２クロマトグラフィにより溶出剤として石油エー
テル／エチルエーテル（５：１）を使用して、この粗生
成物を精製したら、６ｙの生成物（薄黄色の粘液）を得
る。Purification of this crude product by SlO2 chromatography using petroleum ether/ethyl ether (5:1) as eluent gives the product 6y (light yellow slime).
この化合物は、次のような特徴を有していた。This compound had the following characteristics.
元素分析：Ｃｌ３Ｈｌ５ＮＯ４Ｓ（分子量＝２８１．１
３）に対して計算値（％）Ｃ＝５５．４９；Ｈ＝５．３
３：Ｎ＝４．９８実測値（％）Ｃ＝５．３２；Ｈ＝５．
４４；Ｎ＝５．０２赤外線スペクトル（液体フィルム）
３１００ｃｍ−１ （Ｃ−Ｈ芳香族性）：２９７０−２
９５５ｃｍ−１（Ｃ−Ｈ脂肪族性）；１７８５ｃｒＩｔ
−１ （Ｃ＝０）１６７０ｃｍ−１（Ｃ＝０ アミド）
；１１６０ｃｍ−１ （Ｃ＝Ｏ）；８６０ｄ−１ （Ｃ
−Ｈ芳香族性）、Ｈ″ＮＭＲスペクトル（ＣＤＣｌ３中
て測定、内部基準ＴＭＳ）２．２δ （Ｓ，３ＦＩ，Ｃ
ＯＣＨ３）；３．３−３．７δ （Ｍ，２Ｈ，ＡＢＸ系
の鳩部分）；３．８５δ（Ｓ，３ｌｌ，Ｏ一ＣＨ３）；
５．４δ（ダブルＤ，ｌＨ，ＡＢＸ系のＸ部分）；６．
８５−７．３δ（Ｍ，４Ｈ芳香族性）、急性毒性異なつ
た投与経路によるハツカネズミ
（Ｓｗｉｓｓ）及びネズミ（Ｗｉｓｔａｒ）に対する急
性毒．性は、ＬｌｔｃｈｆｉｅｌｄＪ．Ｔ及びＷｉｌｃ
ＯｘＯｎの方法（Ｊ．Ｐｈａｒｍ．Ｅｘｐ．Ｔｈｅｒ．
９６，９９−１１３（１９４９））により測定された。Elemental analysis: Cl3Hl5NO4S (molecular weight = 281.1
Calculated value (%) for 3) C=55.49; H=5.3
3: N=4.98 Actual value (%) C=5.32; H=5.
44; N=5.02 infrared spectrum (liquid film)
3100cm-1 (C-H aromaticity): 2970-2
955 cm-1 (C-H aliphatic); 1785 crIt
-1 (C=0)1670cm-1 (C=0 amide)
;1160cm-1 (C=O);860d-1 (C
-H aromaticity), H″NMR spectrum (measured in CDCl3, internal reference TMS) 2.2δ (S,3FI,C
OCH3); 3.3-3.7δ (M, 2H, pigeon part of ABX system); 3.85δ (S, 3ll, O-CH3);
5.4δ (double D, lH, X part of ABX system);6.
85-7.3δ (M, 4H aromatic), acute toxicity Acute toxicity to Swiss and Wistar by different routes of administration. Gender is according to Lltchfield J. T and Wilc
OxOn method (J. Pharm. Exp. Ther.
96, 99-113 (1949)).
得られた結果を表１に示すが、この表からＳＡ７３４が
非常に小さい毒性を有するに過ぎないことがわかる。
※
表気管支分泌促進活性
気管支分泌促進活性は、下記の投与量においてＳＡ７３
４をカルボキメチルシステイン及びα−メルカプトプロ
ピオニルブリシンと比較するために、マワタリ法（Ｍａ
ｗａｔａｒｉＨ．“゜鹿児島大学医学雑誌８゛−２７，
５６１（１９７６））により雄ネズミに対して経口投与
で測定された。The results obtained are shown in Table 1, from which it can be seen that SA734 has only very low toxicity.
*
Surface bronchial secretagogue activity The bronchial secretagogue activity was determined by SA73 at the following doses.
In order to compare 4 with carboxymethyl cysteine and α-mercaptopropionyl bulycine, the Mawatari method (Ma
watariH. “゜Kagoshima University Medical Journal 8゛-27,
561 (1976)) by oral administration to male rats.
その結果は表２に示す。得られた数値からみて、ＳＡ７
３４は、比較する薬剤を２倍量投与した場合と比べても
、その気管支分泌促進活性において極めて高いというこ
とが明らかである。“生体内での゛流動化活性
流動化効果は、ＳＡ７３４をグアヤコールと比較するた
めに、下記の投与量で経口により投与したのち、ウサギ
の気管気管支粘液に対して微量粘度計により測定された
。The results are shown in Table 2. From the obtained numbers, SA7
It is clear that No. 34 has an extremely high bronchial secretagogue activity even when compared with twice the administration of a comparable drug. “In vivo fluidizing activity: In order to compare SA734 with guaiacol, SA734 was orally administered at the following doses and then measured using a microviscosity meter on rabbit tracheobronchial mucus.
その結果は、表３に示す。下記の数値から明らかなよう
に、ＳＡ７３４の流動化活性は、採用された実験条件下
に等量の投与量で投与されたグアヤコールの場合に比べ
て極めて高いようである。咳止め活性
ＳＡ７３４の咳止め活性は、重量が２００〜３５０ｙて
ある雄雌のウサギに対して腹腔内投与したのち、ＢＯｕ
ｒｅｒ他の方法（ＰｒＯｇ．Ｂｒｉｔ．Ｐｈａｒｍａｃ
．ＳＯｃ．Ａｐｒ．ｌ９７Ｏ）により、クエン酸エアゾ
ールで誘発される咳の方法を利用用してテストされた。The results are shown in Table 3. As is evident from the figures below, the mobilizing activity of SA734 appears to be much higher than that of guaiacol administered at an equivalent dose under the experimental conditions employed. Cough suppressant activity The cough suppressant activity of SA734 was determined by intraperitoneal administration to male and female rabbits weighing 200 to 350 y.
rer et al. method (PrOg.Brit.Pharmac
．． SOc. Apr. (197O) using a citrate aerosol-induced cough method.
対照基準としては、１２．５ＴｒＬ９／Ｋ９の投与量に
おいてコデインで処理された一群のウサギが利用され得
られた結果から、ＳＡ７３４は、対照と比較した場合に
統計的に顕著な、またコデインのような一定の効能を有
する基準と比較した場合に百分率的に非常に高くかつ低
くない咳止め活性を示すということがわかる。薬動力学
的特性
薬動力学的テストを、ＳＡ７３４を経口投与し、チアゾ
リジンーカルボン酸を等モリ投与した後、動物に対して
行つたら、ＳＡ７３４がそのものとして吸収されるとい
うことがわかつた。As a reference standard, a group of rabbits treated with codeine at a dose of 12.5 TrL9/K9 was utilized and the results obtained showed that SA734 had a statistically significant and similar effect to codeine when compared to the control. It can be seen that the antitussive activity is very high and not low in percentage when compared with standards having a certain efficacy. Pharmacodynamic Properties Pharmacodynamic tests were performed on animals after oral administration of SA734 and equimolar administration of thiazolidine-carboxylic acid and it was found that SA734 was absorbed as such.
濃度が長い間存在すること及び高い生物利用性を有する
ことが見い出されるために、２つの処理を施したチアゾ
リジンカルボン酸の原形質レベルは、ＳＡ７３４の投与
後に非常に良いパターンを示す。その上、ＳＡ７３４を
用いた場合には、肺レベルに−おけるチアゾリジンカル
ボン酸の高濃度は、おそらくこの器官に対する著しい屈
動性により注目された。The cytoplasmic levels of thiazolidine carboxylic acids with the two treatments show a very good pattern after administration of SA734, since the concentrations are found to be present for a long time and have high bioavailability. Moreover, when using SA734, the high concentration of thiazolidine carboxylic acid at the lung level was noted, probably due to the significant tropism towards this organ.
また本発明は、人間治療におけるＳＡ７３４の利用に直
結する全ての工業的に適用しうる面についても言及する
。The invention also refers to all industrially applicable aspects directly related to the use of SA734 in human therapy.
したがつて本発明の本質的な点は、ＳＡ７３４を予じめ
決められた量、特に１００〜２５０ｍ９含む製薬的処方
により与えられる。The essence of the invention is therefore provided by a pharmaceutical formulation containing a predetermined amount of SA734, in particular 100-250 m9.
本発明の目的化合物は、錠剤、カプセル、一服分の袋、
注射又はエアゾールのための小瓶、座剤の形態にした上
で、経口、非経口、直腸経路又は吸入経路で投与される
。The object compound of the present invention can be used in tablets, capsules, single-dose bags,
It is administered by oral, parenteral, rectal or inhalation routes in the form of vials for injection or aerosol, suppositories.
Claims (1)
ゾリジン−カルボキシレート化合物２ Ｎ−アセチル−
４−チアゾリジン−カルボン酸をグアヤコールでエステ
ル化することにより、一般式▲数式、化学式、表等があ
ります▼ で示される化合物を製造する方法。 ３ 無水の中性溶液中で反応を行うようにしたことを特
徴とする特許請求の範囲第２項記載の方法。 ４ カルボニル−ジイミタゾール又は混合された無水物
を生成することのできる他の公知の試薬の存在の下に反
応を行うようにしたことを特徴とする特許請求の範囲第
２項又は３項記載の方法。 ５ 活性成分として、一般式 ▲数式、化学式、表等があります▼ で示されるグアヤコールＮ−アセチル−４−チアゾリジ
ン−カルボキシレートを含有することを特徴とする気管
支分泌促進活性、気管気管支の粘液流動化活性及び咳止
め活性を有する製薬組成物。 ６ カプセル化、錠剤、シロツプ、一服分の袋、小瓶、
座剤等の形態にすることを特徴とする特許請求の範囲第
５項記載の製薬組成物。[Claims] 1. A novel guaiacol N-acetyl-4-thiazolidine-carboxylate compound represented by the general formula ▲ Numerical formula, chemical formula, table, etc. ▼ 2 N-acetyl-
A method for producing a compound represented by the general formula ▲ Numerical formula, chemical formula, table, etc. ▼ by esterifying 4-thiazolidine-carboxylic acid with guaiacol. 3. The method according to claim 2, wherein the reaction is carried out in an anhydrous neutral solution. 4. Process according to claim 2 or 3, characterized in that the reaction is carried out in the presence of carbonyl-diimitazole or other known reagents capable of producing mixed anhydrides. . 5. Bronchial secretion promoting activity, tracheobronchial mucus fluidization characterized by containing guaiacol N-acetyl-4-thiazolidine-carboxylate represented by the general formula ▲mathematical formula, chemical formula, table, etc.▼ as an active ingredient. A pharmaceutical composition having antitussive and antitussive activity. 6 Encapsulations, tablets, syrups, single-dose bags, vials,
The pharmaceutical composition according to claim 5, which is in the form of a suppository or the like.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22764/82A IT1190945B (en) | 1982-08-06 | 1982-08-06 | COMPOUND WITH BRONCHO-SECRETOGOGUE, FLUIDIFYING AND ANTITUSSIGENIC ACTION, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT |
| IT22764-A/82 | 1982-08-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5944367A JPS5944367A (en) | 1984-03-12 |
| JPS6050789B2 true JPS6050789B2 (en) | 1985-11-11 |
Family
ID=11200186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58142379A Expired JPS6050789B2 (en) | 1982-08-06 | 1983-08-03 | Novel compound having bronchial secretagogue activity, mucus fluidizing activity and cough suppressant activity, process for producing the same, and pharmaceutical composition containing the same |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS6050789B2 (en) |
| DE (1) | DE3325677A1 (en) |
| ES (1) | ES8502429A1 (en) |
| IT (1) | IT1190945B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63168794U (en) * | 1987-04-21 | 1988-11-02 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE74354T1 (en) * | 1988-06-29 | 1992-04-15 | Yason Srl | N-CARBETHOXY-4-THIAZOLINE CARBONIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE AS A MEDICINAL PRODUCT. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR8266M (en) * | 1968-12-31 | 1970-10-26 | ||
| FR2222087B1 (en) * | 1973-03-22 | 1976-04-09 | Ferlux |
-
1982
- 1982-08-06 IT IT22764/82A patent/IT1190945B/en active
-
1983
- 1983-07-15 DE DE19833325677 patent/DE3325677A1/en active Granted
- 1983-08-03 JP JP58142379A patent/JPS6050789B2/en not_active Expired
- 1983-08-04 ES ES524727A patent/ES8502429A1/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63168794U (en) * | 1987-04-21 | 1988-11-02 |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1190945B (en) | 1988-02-24 |
| ES524727A0 (en) | 1985-01-01 |
| ES8502429A1 (en) | 1985-01-01 |
| IT8222764A0 (en) | 1982-08-06 |
| JPS5944367A (en) | 1984-03-12 |
| DE3325677A1 (en) | 1984-02-09 |
| DE3325677C2 (en) | 1988-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0145953B1 (en) | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide | |
| US5663335A (en) | Immunosuppressive compounds and methods | |
| JPS58162554A (en) | 2-(p-isobutylphenyl)propionic acid derivative, manufacture and medicine | |
| BR112012030010A2 (en) | 5-fluorine-1h-pyrazolopyridines substituted and their use | |
| JPH07500355A (en) | Nitric acid ester of 2-(2,6-di-halo-phenylamino)phenylacetic acid derivative and method for producing the same | |
| CA2941415A1 (en) | Methods for treating neurological disorders | |
| JPH0326183B2 (en) | ||
| JPH05112566A (en) | Pyrazolopyridine compound and its production | |
| KR960012204B1 (en) | Beta-aminoethyl substituted phenyl compound and anti-inflammatory or analgesic compositions containing them | |
| US4670469A (en) | Hydroxamic acid and pharmaceutical preparations containing the same | |
| JPS61180784A (en) | Thiophene derivative and medicinal composition | |
| JPS58194859A (en) | 1-carboxyalkanoylindoline-2-carboxylic acid ester, manufacture and medicine | |
| JPS6050789B2 (en) | Novel compound having bronchial secretagogue activity, mucus fluidizing activity and cough suppressant activity, process for producing the same, and pharmaceutical composition containing the same | |
| US4479957A (en) | Use of vindesine in treating acute lymphatic leukemia and _other susceptible neoplasms | |
| PT97487A (en) | PROCESS FOR THE PREPARATION OF SALTS OF FURANO DERIVATIVES AND A BISMUTAL COMPLEX WITH A THERAPEUTICALLY USEFUL CARBOXYL ACID | |
| JP2005511611A (en) | Amine salts of integrin receptor antagonists | |
| JPS6270335A (en) | Bicyclic aryl ether derivative, manufacture and use | |
| EP0007648B1 (en) | New acylureas with pharmaceutical activity, the process for their preparation, and pharmaceutical compositions which contain them | |
| JPS58188847A (en) | Peptide derivative | |
| JPH06279432A (en) | New compound and anticancer agent containing the compound as active component | |
| US5182300A (en) | Furosemide salts | |
| JPS6160816B2 (en) | ||
| EP0047358A1 (en) | Indol acetic derivatives, process for producing the same and pharmaceutical compositions comprising the same | |
| JPH01149788A (en) | Novel morphine derivative | |
| AU4867799A (en) | Injectable sodium acetylsalicylate composition and method |